ArticleClinical pharmacokinetics2019
Levothyrox
Article in Clinical pharmacokinetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A Comparative pH-Dissolution Profile Analysis of Selected Commercial Levothyroxine Formulations in Lebanon Using Anion-Exchange HPLC Method: Implication on Interchangeability.Advances in pharmacological and pharmaceutical sciences · 2025Article
- Advancing drug safety and mitigating health concerns: High-resolution mass spectrometry in the levothyroxine case study.Journal of pharmaceutical analysis · 2024Article
- A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Article
- Comment on "Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology".European journal of drug metabolism and pharmacokinetics · 2023Article
- Response to Comment on "Interchangeability Between Generic and Reference Products: Limits of Average Bioequivalence Methodology".European journal of drug metabolism and pharmacokinetics · 2023Article
- Pharmacokinetics and Generic Drug Switching: A Regulator's View.Clinical pharmacokinetics · 2020Article
- Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands.Clinical and translational science · 2020Article
- Comment on "LevothyroxClinical pharmacokinetics · 2020Article
- Authors' Reply to Nicolas: "Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"Clinical pharmacokinetics · 2020Article
- Comment on "LevothyroxClinical pharmacokinetics · 2020Article
- Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"Clinical pharmacokinetics · 2020Article
- Stability and Compatibility Studies of Levothyroxine Sodium in Solid Binary Systems-Instrumental Screening.Pharmaceutics · 2020Article
- Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?Clinical pharmacokinetics · 2020Article
- Authors' Reply to Lechat et al.: "LevothyroxClinical pharmacokinetics · 2019Article
- Comment on: "LevothyroxClinical pharmacokinetics · 2019Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In France, more than 2.5 million patients are currently treated with levothyroxine, mainly as the marketed product Levothyrox
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.